Report Detail
Global Infliximab Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
- RnM4519347 |
- 06 March, 2023 |
- Global |
- 91 Pages |
- GIR (Global Info Research) |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Infliximab Biosimilar market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Infliximab Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Infliximab Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Infliximab Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Infliximab Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Infliximab Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Infliximab Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Infliximab Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Napp Pharmaceuticals Group, Janssen Biotech, Alvogen, Merck and Celltrion, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Infliximab Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
CT-P13/infliximab-dyyb
Remsima
Inflectra
Market segment by Application
Crohn's Disease
Rheumatoid Arthritis
Ulcerative Colitis
Ankylosing Spondylitis
Plaque Psoriasis
Others
Major players covered
Napp Pharmaceuticals Group
Janssen Biotech
Alvogen
Merck
Celltrion
Pfizer(Ac Hospira)
Nippon Kayaku
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Infliximab Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Infliximab Biosimilar, with price, sales, revenue and global market share of Infliximab Biosimilar from 2018 to 2023.
Chapter 3, the Infliximab Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Infliximab Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Infliximab Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Infliximab Biosimilar.
Chapter 14 and 15, to describe Infliximab Biosimilar sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope of Infliximab Biosimilar
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Infliximab Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
- 1.3.2 CT-P13/infliximab-dyyb
- 1.3.3 Remsima
- 1.3.4 Inflectra
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Infliximab Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
- 1.4.2 Crohn's Disease
- 1.4.3 Rheumatoid Arthritis
- 1.4.4 Ulcerative Colitis
- 1.4.5 Ankylosing Spondylitis
- 1.4.6 Plaque Psoriasis
- 1.4.7 Others
- 1.5 Global Infliximab Biosimilar Market Size & Forecast
- 1.5.1 Global Infliximab Biosimilar Consumption Value (2018 & 2022 & 2029)
- 1.5.2 Global Infliximab Biosimilar Sales Quantity (2018-2029)
- 1.5.3 Global Infliximab Biosimilar Average Price (2018-2029)
2 Manufacturers Profiles
- 2.1 Napp Pharmaceuticals Group
- 2.1.1 Napp Pharmaceuticals Group Details
- 2.1.2 Napp Pharmaceuticals Group Major Business
- 2.1.3 Napp Pharmaceuticals Group Infliximab Biosimilar Product and Services
- 2.1.4 Napp Pharmaceuticals Group Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.1.5 Napp Pharmaceuticals Group Recent Developments/Updates
- 2.2 Janssen Biotech
- 2.2.1 Janssen Biotech Details
- 2.2.2 Janssen Biotech Major Business
- 2.2.3 Janssen Biotech Infliximab Biosimilar Product and Services
- 2.2.4 Janssen Biotech Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.2.5 Janssen Biotech Recent Developments/Updates
- 2.3 Alvogen
- 2.3.1 Alvogen Details
- 2.3.2 Alvogen Major Business
- 2.3.3 Alvogen Infliximab Biosimilar Product and Services
- 2.3.4 Alvogen Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.3.5 Alvogen Recent Developments/Updates
- 2.4 Merck
- 2.4.1 Merck Details
- 2.4.2 Merck Major Business
- 2.4.3 Merck Infliximab Biosimilar Product and Services
- 2.4.4 Merck Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.4.5 Merck Recent Developments/Updates
- 2.5 Celltrion
- 2.5.1 Celltrion Details
- 2.5.2 Celltrion Major Business
- 2.5.3 Celltrion Infliximab Biosimilar Product and Services
- 2.5.4 Celltrion Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.5.5 Celltrion Recent Developments/Updates
- 2.6 Pfizer(Ac Hospira)
- 2.6.1 Pfizer(Ac Hospira) Details
- 2.6.2 Pfizer(Ac Hospira) Major Business
- 2.6.3 Pfizer(Ac Hospira) Infliximab Biosimilar Product and Services
- 2.6.4 Pfizer(Ac Hospira) Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.6.5 Pfizer(Ac Hospira) Recent Developments/Updates
- 2.7 Nippon Kayaku
- 2.7.1 Nippon Kayaku Details
- 2.7.2 Nippon Kayaku Major Business
- 2.7.3 Nippon Kayaku Infliximab Biosimilar Product and Services
- 2.7.4 Nippon Kayaku Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
- 2.7.5 Nippon Kayaku Recent Developments/Updates
3 Competitive Environment: Infliximab Biosimilar by Manufacturer
- 3.1 Global Infliximab Biosimilar Sales Quantity by Manufacturer (2018-2023)
- 3.2 Global Infliximab Biosimilar Revenue by Manufacturer (2018-2023)
- 3.3 Global Infliximab Biosimilar Average Price by Manufacturer (2018-2023)
- 3.4 Market Share Analysis (2022)
- 3.4.1 Producer Shipments of Infliximab Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
- 3.4.2 Top 3 Infliximab Biosimilar Manufacturer Market Share in 2022
- 3.4.2 Top 6 Infliximab Biosimilar Manufacturer Market Share in 2022
- 3.5 Infliximab Biosimilar Market: Overall Company Footprint Analysis
- 3.5.1 Infliximab Biosimilar Market: Region Footprint
- 3.5.2 Infliximab Biosimilar Market: Company Product Type Footprint
- 3.5.3 Infliximab Biosimilar Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Infliximab Biosimilar Market Size by Region
- 4.1.1 Global Infliximab Biosimilar Sales Quantity by Region (2018-2029)
- 4.1.2 Global Infliximab Biosimilar Consumption Value by Region (2018-2029)
- 4.1.3 Global Infliximab Biosimilar Average Price by Region (2018-2029)
- 4.2 North America Infliximab Biosimilar Consumption Value (2018-2029)
- 4.3 Europe Infliximab Biosimilar Consumption Value (2018-2029)
- 4.4 Asia-Pacific Infliximab Biosimilar Consumption Value (2018-2029)
- 4.5 South America Infliximab Biosimilar Consumption Value (2018-2029)
- 4.6 Middle East and Africa Infliximab Biosimilar Consumption Value (2018-2029)
5 Market Segment by Type
- 5.1 Global Infliximab Biosimilar Sales Quantity by Type (2018-2029)
- 5.2 Global Infliximab Biosimilar Consumption Value by Type (2018-2029)
- 5.3 Global Infliximab Biosimilar Average Price by Type (2018-2029)
6 Market Segment by Application
- 6.1 Global Infliximab Biosimilar Sales Quantity by Application (2018-2029)
- 6.2 Global Infliximab Biosimilar Consumption Value by Application (2018-2029)
- 6.3 Global Infliximab Biosimilar Average Price by Application (2018-2029)
7 North America
- 7.1 North America Infliximab Biosimilar Sales Quantity by Type (2018-2029)
- 7.2 North America Infliximab Biosimilar Sales Quantity by Application (2018-2029)
- 7.3 North America Infliximab Biosimilar Market Size by Country
- 7.3.1 North America Infliximab Biosimilar Sales Quantity by Country (2018-2029)
- 7.3.2 North America Infliximab Biosimilar Consumption Value by Country (2018-2029)
- 7.3.3 United States Market Size and Forecast (2018-2029)
- 7.3.4 Canada Market Size and Forecast (2018-2029)
- 7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
- 8.1 Europe Infliximab Biosimilar Sales Quantity by Type (2018-2029)
- 8.2 Europe Infliximab Biosimilar Sales Quantity by Application (2018-2029)
- 8.3 Europe Infliximab Biosimilar Market Size by Country
- 8.3.1 Europe Infliximab Biosimilar Sales Quantity by Country (2018-2029)
- 8.3.2 Europe Infliximab Biosimilar Consumption Value by Country (2018-2029)
- 8.3.3 Germany Market Size and Forecast (2018-2029)
- 8.3.4 France Market Size and Forecast (2018-2029)
- 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
- 8.3.6 Russia Market Size and Forecast (2018-2029)
- 8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
- 9.1 Asia-Pacific Infliximab Biosimilar Sales Quantity by Type (2018-2029)
- 9.2 Asia-Pacific Infliximab Biosimilar Sales Quantity by Application (2018-2029)
- 9.3 Asia-Pacific Infliximab Biosimilar Market Size by Region
- 9.3.1 Asia-Pacific Infliximab Biosimilar Sales Quantity by Region (2018-2029)
- 9.3.2 Asia-Pacific Infliximab Biosimilar Consumption Value by Region (2018-2029)
- 9.3.3 China Market Size and Forecast (2018-2029)
- 9.3.4 Japan Market Size and Forecast (2018-2029)
- 9.3.5 Korea Market Size and Forecast (2018-2029)
- 9.3.6 India Market Size and Forecast (2018-2029)
- 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
- 9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
- 10.1 South America Infliximab Biosimilar Sales Quantity by Type (2018-2029)
- 10.2 South America Infliximab Biosimilar Sales Quantity by Application (2018-2029)
- 10.3 South America Infliximab Biosimilar Market Size by Country
- 10.3.1 South America Infliximab Biosimilar Sales Quantity by Country (2018-2029)
- 10.3.2 South America Infliximab Biosimilar Consumption Value by Country (2018-2029)
- 10.3.3 Brazil Market Size and Forecast (2018-2029)
- 10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
- 11.1 Middle East & Africa Infliximab Biosimilar Sales Quantity by Type (2018-2029)
- 11.2 Middle East & Africa Infliximab Biosimilar Sales Quantity by Application (2018-2029)
- 11.3 Middle East & Africa Infliximab Biosimilar Market Size by Country
- 11.3.1 Middle East & Africa Infliximab Biosimilar Sales Quantity by Country (2018-2029)
- 11.3.2 Middle East & Africa Infliximab Biosimilar Consumption Value by Country (2018-2029)
- 11.3.3 Turkey Market Size and Forecast (2018-2029)
- 11.3.4 Egypt Market Size and Forecast (2018-2029)
- 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
- 11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
- 12.1 Infliximab Biosimilar Market Drivers
- 12.2 Infliximab Biosimilar Market Restraints
- 12.3 Infliximab Biosimilar Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
- 12.5 Influence of COVID-19 and Russia-Ukraine War
- 12.5.1 Influence of COVID-19
- 12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
- 13.1 Raw Material of Infliximab Biosimilar and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Infliximab Biosimilar
- 13.3 Infliximab Biosimilar Production Process
- 13.4 Infliximab Biosimilar Industrial Chain
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Infliximab Biosimilar Typical Distributors
- 14.3 Infliximab Biosimilar Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Infliximab Biosimilar. Industry analysis & Market Report on Infliximab Biosimilar is a syndicated market report, published as Global Infliximab Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Infliximab Biosimilar market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
